Studies have shown that the PRMT-6PGD/ENO1 axis is critical for lung cancer progression, and inhibiting the signaling of this axis can enhance antitumor effect of cisplatin in preclinical lung cancer models [42]. The gene discussed is ENO1; the disease is lung carcinoma.